HT25 is your chance to engage with a diverse, international community of scientists, clinicians, diagnosticians, industry leaders, and data experts. This is a rare opportunity to form collaborations that bridge basic research, translational science, and clinical innovation in early lung cancer.
Gain cutting-edge insights into the molecular, genomic, transcriptomic, and immune mechanisms that drive early lung carcinogenesis.
Advance Biomarker and Diagnostic InnovationExplore the current landscape and emerging advances in biomarker discovery—including liquid biopsies and AI-powered diagnostics—that are poised to revolutionize early detection, prognostication, and personalized care strategies.
Learn from case studies, expert panels, and translational research sessions that showcase how scientific breakthroughs can be effectively integrated into clinical practice to improve outcomes for patients at the earliest stages of disease.
Dive into the latest therapeutic approaches, including targeted therapies and immunotherapy tailored for early-stage lung cancer, and uncover promising new drug targets and strategies for intercepting disease progression.
Dear Colleagues and Friends,
Welcome to the IASLC 2025 Hot Topic in Basic and Translational Science Meeting: Unraveling Precancer and Early-stage Lung Cancer: From Biology to Clinical Application. We are thrilled to have you join this dynamic gathering of scientists, clinicians, and thought leaders dedicated to advancing our understanding of early-stage lung cancer. Over the course of the meeting, we will delve into the molecular and cellular mechanisms that drive early lung carcinogenesis, explore emerging biomarkers and diagnostic tools, and examine the evolution, progression, and therapeutic vulnerabilities of early lung tumors. Through expert presentations, panel discussions, and case studies, we aim to bridge the gap between cutting-edge science and its clinical application—ultimately moving closer to personalized interception and improved outcomes for patients.
We look forward to welcoming you to Tokyo, Japan, in November 2025!
Stay Connected
© 2025 International Association for the Study of Lung Cancer - IASLC HT 2025